Engagement and partnership with consumers and communities in the co-design and conduct of Research: Lessons from the INtravenous iron polymaltose for First Nations Australian patients with high FERRitin levels on haemodialysis (INFERR) clinical trial

Stephanie Long, Cheryl Ross, J Koops, Katherine Coulthard, Jane Nelson, Archana Khadka Shapkota, Leiana Hewett, Jaclyn Tate-Baker, Jessica Graham, Rose Mukula, Cynthia Tetteh, Libby Hoppo, Cherian Sajiv, Basant Pawar, Heidi Lee Chmielewski, Lorna Murakami Gold, Geetha Rathnayake, Bianca Heron, Teana Brewster-O’Brien, Vijay Karepalli, Louise Maple‐Brown, Robert A. Batey, Peter W. G. Morris, Jane Davies, David Kiran Fernandes, Sajan Thomas, Asanga Abeyaratne, Paul Lawton, Federica Barzi, Sean Taylor, Mark Mayo, Alan Cass, Sandawana William MajoniResearch 2024 · DOI · OpenAlex

Abstract

Active consumer and community partnership is critical in research conduct to ensure research impact. Strong partnership with consumers in the INFERR clinical trial has demonstrated that First Nations Consumers will engage in research they understand, that addresses health priorities for them and where they feel respected, listened to, and empowered to achieve change.

Introduction

Genuine co-design in clinical research remains a challenge, often falling into tokenistic "patient involvement." The INFERR clinical trial serves as a landmark case study in moving beyond these limitations. By establishing independent Indigenous Reference Groups (IRGs), the trial embedded First Nations leadership into its governance, ensuring the research was both culturally safe and clinically relevant. This approach not only facilitated high recruitment rates but also enabled the rapid translation of findings into national clinical guidelines.

The "Ferritin Paradox" and the Trust Gap

In the Northern Territory of Australia, First Nations patients on hemodialysis frequently encounter a "ferritin paradox." While ferritin typically measures iron stores, chronic inflammation in this population often leads to high levels regardless of actual iron overload. This complicates the diagnosis and treatment of iron deficiency anemia, as standard guidelines fail to account for this specific physiological context.

Furthermore, a historical "trust gap" exists between researchers and Indigenous communities. Traditional models often lack cultural safety, resulting in poor engagement and findings that do not translate into improved health outcomes. The INFERR trial addressed a fundamental question: How can a clinical trial be designed to be both scientifically rigorous and culturally safe for First Nations Australians?

Methodology: A Qualitative Framework for Engagement

The INFERR trial utilized a qualitative framework centered on the establishment of two Indigenous Reference Groups (IRGs)—one for the "Top End" and one for Central Australia—to respect regional and cultural diversity.

Governance and engagement framework for the INFERR clinical trial

The core pillars of this methodology included:

  • Supportive Infrastructure: Each IRG was assisted by a First Nations Research Officer (FNRO) and an independent First Nations academic, who served as vital links between clinical concepts and community priorities.
  • Co-Design of Materials: IRGs overhauled all participant-facing documents. Dense text was replaced with oral consent processes, pictorial aids, and local Tiwi artwork to ensure accessibility.
  • Integrated Governance: IRG chairs held seats on the Trial Management Committee (TMC), providing a direct pathway for community advice to reach executive decision-makers.
  • Reciprocity: Meetings provided immediate value to members through educational sessions with specialists like nutritionists and transplant coordinators.

Key Results and Clinical Translation

The trial has seen significant success in recruitment and immediate clinical impact. As of June 2024, over 440 participants have been recruited toward a goal of 576.

A critical sub-study comparing two ferritin assay platforms revealed a consistent 36–44% bias between them. This finding was so impactful that it led to:

  1. Immediate adjustments in the INFERR trial’s inclusion criteria.
  2. Updates to standard national clinical guidelines for managing ferritin levels in the Northern Territory.

Despite the challenges of the COVID-19 pandemic and extreme weather in Central Australia, the trial maintained high engagement and quorum in its governance meetings.

Discussion: Insights into Cultural Safety

The INFERR experience highlights that cultural safety is a power shift. It is defined by overcoming power imbalances between researchers and participants, where the participant determines if an interaction is safe.

The IRGs emphasized that knowledge is often passed on orally in First Nations communities; thus, written-only consent processes can be a significant barrier. Interestingly, the Top End IRG chose a name focused on the medical concept ("Iron") rather than ethnicity, signaling that their lived experience of health was their primary contribution.

The effectiveness of this model has led other research teams (e.g., those working on COVID-19 vaccines) to seek advice from these IRGs, demonstrating the scalability of a centralized hub for community engagement.

Conclusion and Future Directions

While successful, genuine engagement requires significant resources. Funding for participant compensation, travel, and administrative support is often underestimated in research grants. Additionally, translating materials into the numerous distinct First Nations languages remains a resource-intensive challenge.

Looking forward, the team is seeking funding for a dedicated liver clinic for dialysis patients, addressing the high prevalence of comorbid liver disease identified during the trial. The INFERR trial serves as a powerful reminder that in clinical research, the "how" of the process is just as critical as the "what" of the data.

Summary updated

Abstract

Active consumer and community partnership is critical in research conduct to ensure research impact. Strong partnership with consumers in the INFERR clinical trial has demonstrated that First Nations Consumers will engage in research they understand, that addresses health priorities for them and where they feel respected, listened to, and empowered to achieve change.
BibTeX
@inproceedings{long2024engagement,
  author = {Stephanie Long and Cheryl Ross and J Koops and Katherine Coulthard and Jane Nelson and Archana Khadka Shapkota and Leiana Hewett and Jaclyn Tate-Baker and Jessica Graham and Rose Mukula and Cynthia Tetteh and Libby Hoppo and Cherian Sajiv and Basant Pawar and Heidi Lee Chmielewski and Lorna Murakami Gold and Geetha Rathnayake and Bianca Heron and Teana Brewster-O’Brien and Vijay Karepalli and Louise Maple‐Brown and Robert A. Batey and Peter W. G. Morris and Jane Davies and David Kiran Fernandes and Sajan Thomas and Asanga Abeyaratne and Paul Lawton and Federica Barzi and Sean Taylor and Mark Mayo and Alan Cass and Sandawana William Majoni},
  title = {{Engagement and partnership with consumers and communities in the co-design and conduct of Research: Lessons from the INtravenous iron polymaltose for First Nations Australian patients with high FERRitin levels on haemodialysis (INFERR) clinical trial}},
  booktitle = {Research},
  year = {2024},
  doi = {10.1186/s40900-024-00608-9},
}
Figure